Mendelian randomization and statin-trial estimates of LDL's cardiovascular effect are mutually consistent once duration of exposure is accounted for
5 events · 2 assessments · 2 decisions
Reworded canonical form, reassessed (supported/0.6 -> verified/0.85), re-evaluated argument (holds with caveats -> holds), set importance 0.35/contestation 0.15
Triggered by a subclaim_change flagging the verified "roughly threefold greater" MR subclaim as apparently opposed to this claim under a SUPPORTS edge, plus a Curator ruling. The Curator adjudicated: no merge, no split, SUPPORTS edges correct; the two claims are distinct and not negations provided this node is read as the reconciliation (mutual consistency once exposure duration is accounted for), not raw per-unit equality. The Curator directed sharpening the canonical wording, which was the source of the apparent contradiction.\n\nActions: (1) Reworded canonical form from "...per-unit effect...agree with...trial estimates" to "...mutually consistent once duration of exposure is accounted for", stating the reading actually assessed without changing the claim's identity (per Curator ruling this is not an individuation/negation change). (2) With the interpretation ambiguity removed, lifted the verdict from the interpretation-hedged supported/0.6 to verified/0.85: the two verified subclaims plus the well-established duration-dependence premise jointly entail the reconciliation, which is the settled view (Ference 2012 JACC, 2017 EAS consensus, CTT 21-trial duration meta-analysis). Confidence held to 0.85 (not higher) because the load-bearing duration subclaim is not yet independently assessed and no fresh adversarial search was warranted at this importance. (3) Re-evaluated the reconciliation argument to "holds" (from "holds_with_caveats"): the former caveat is now carried by the claim wording itself. (4) Set importance 0.35, contestation 0.15: notable, consequential but uncontested among researchers. SUPPORTS structure left intact per Curator ruling; no CONTRADICTS re-edge needed.
Reassessed: Supported → Verified
verdict confidence 0.60 → 0.85 · credence 0.92
Mendelian randomization and randomized statin-trial estimates of LDL cholesterol's effect on cardiovascular risk are mutually consistent once the duration of LDL exposure is taken into account, and this reconciliation is the settled view among lipid researchers. The two evidence streams differ sharply in raw magnitude: statin trials show that lowering LDL by 1 mmol/L reduces major vascular events by about a fifth over roughly five years, whereas genetic studies estimate a roughly threefold greater risk reduction per mmol/L. That gap is not a conflict but an expected consequence of what each method measures: genetic variants proxy lifelong lower LDL, trials capture only a few years of treatment, and the per-unit benefit grows with the duration of exposure. Ference and colleagues (JACC 2012) and the 2017 European Atherosclerosis Society consensus statement both present the genetic and trial evidence as concordant parts of a single dose- and duration-dependent relationship between cumulative LDL exposure and atherosclerotic disease. No credible party disputes either the underlying figures or their reconciliation; the claim is read here as an assertion of consistency, not of numerical equality of the per-unit coefficients (which plainly differ).
Structured and assessed
First pass. Decomposed into three subclaims under one "for" argument (reconciliation via cumulative lifelong exposure): linked existing verified claim on the ~20%-per-mmol/L statin-trial estimate (d81f89e3), and created two novel nodes confirmed by the Matcher: MR estimates ~3-fold greater reduction per mmol/L than trials (90d84763), and per-unit benefit increases with exposure duration (d1491505). Both scored ~0.3-0.35 importance / 0.2 contestation (established, uncontested facts). Wrote and evaluated the argument (holds_with_caveats). Assessment: supported, confidence 0.6, credence omitted (interpretation-dependent). Evidence base: Ference JACC 2012 (54.5% per mmol/L, explicitly ~3x statins), 21-trial meta-analysis (RR grows 12%→29% with duration), 60-RCT meta-analysis, and EAS Consensus Panel log-linear dose-response. The claim is well supported as a consistency/triangulation statement but would be contradicted if read as raw per-unit magnitude equality; hence moderate confidence and a Curator escalation over the wording ambiguity. Set claim importance 0.35, contestation 0.3.
Assessed Supported
verdict confidence 0.60
Whether Mendelian randomization and randomized-trial estimates of LDL's per-unit effect "agree" depends on what is being compared. At face value the raw per-unit magnitudes diverge sharply: pooled statin trials show roughly a fifth (about 20%) lower risk of major vascular events per mmol/L LDL reduction over about five years, whereas Mendelian randomization estimates roughly a 50% or greater reduction per mmol/L, on the order of a threefold larger effect. That gap is not, however, treated as a genuine disagreement. It is expected and quantitatively explained: the per-unit benefit of lower LDL grows with the duration of exposure (trial estimates rise from roughly 12% at one year toward 23% at five years and higher thereafter), and genetic variants proxy lifelong lower LDL while trials capture only a few years of treatment begun later in life. Once cumulative exposure and a log-linear dose-response are accounted for, the genetic and trial evidence are mutually consistent and are widely presented as convergent support for LDL's causal role. The claim is therefore well supported in its intended sense, that the two lines of evidence agree and reinforce one another, but it would be misleading read as a claim that the raw per-unit coefficients match, since they differ by about threefold. The reconciliation is settled science; the residual uncertainty is interpretive rather than empirical.
Claim entered the graph